Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253528 | 0.90 | DNM1 (0.50) | CA1DNM1CA9CA2FAAH | |
| SCHEMBL245935 | 0.83 | — | — | |
| SCHEMBL16090593 | 0.81 | MEN1 (0.42) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL11989255 | 0.79 | MEN1 (0.44) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL14040885 | 0.77 | CA1 (0.40) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL856357 | 0.77 | MEN1 (0.40) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL241253 | 0.77 | MEN1 (0.40) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL293640 | 0.77 | MEN1 (0.40) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL19169971 | 0.77 | FAAH (0.41) | MEN1KMT2ATDP1CA1DNM1 | |
| SCHEMBL293641 | 0.77 | CA2 (0.48) | MEN1KMT2ATDP1CA1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| EP-2588454-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000945-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | WO | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-6642223-B2 | A benzoazepin or benzodiazepin derivatives, shows excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1221440-A1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | Otsuka Pharmaceutical Company, Limited (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-20020049194-A1 | Benzoheterocyclic derivatives | OGAWA HIDENORI (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6335327-B1 | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6096735-A | Benzoheterocyclic derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| EP-0765314-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034540-A1 | BENZOHETEROCYCLIC DERIVATIVES USEFUL AS VASOPRESSIN OR OXYTOCIN MODULATORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | MEN1 2203/4885KMT2A 2205/4885TDP1 204/4885 |
| US-20020049194-A1 | Benzoheterocyclic derivatives | AVPR2, AVPR1A, AVPR1B | MEN1 1227/4885KMT2A 4490/4885TDP1 3264/4885 |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | MEN1 2203/4885KMT2A 2205/4885TDP1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.